Feb 26, 2021 · 50 to 70 mg/m2 by slow IV infusion once every 3 to 4 weeks; for heavily pretreated patients, an initial dose of 50 mg/m2 by slow IV infusion once every 4 weeks is recommended. Comments: -The dosing presented is manufacturer suggested. -Other doses and combination regimens have been used. Use: For advanced bladder cancer.
Oct 07, 2021 · 1 dose of cisplatin in humans measured as mg per skin area (mg/m 2) was translated in mg/kg using the correction factor for human body weight of 60 kg and the body surface area 1.62 m 2 (K m = 37) . #data from 1978 when supportive care measures were not established; * therapy cisplatin/docetaxel (lung cancer); cisplatin 2 h infusion every 3 weeks, …
Cisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced disease that cannot be treated with other therapies, such as surgery or radiation therapy. Ovarian cancer that has metastasized (spread to other parts of the body). It is used with other drugs in patients who have ...
Oct 05, 2014 · Cisplatin has a molecular weight of 301.1 gm/mol, a density of 3.74 g/cm 3, a melting point of 270° C, a log K ow of -2.19 and a water solubility of 2.53 g/L at 25° C (HSDB 2009). Cisplatin was first synthesized by M. Peyrone in 1844 and its chemical structure was first elucidated by Alfred Werner in 1893.
Cisplatin Injection should be administered as a single agent at a dose of 50 to 70 mg/m2 IV per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy.
You usually have GC chemotherapy as cycles of treatment. Each cycle takes 3 weeks. You usually have between 4 to 6 cycles of treatment taking from 3 to 6 months.
Cisplatin is typically given once every 3-4 weeks (every 21-28 days), but may occasionally be given weekly (every 7 days). The most appropriate route of administration and total number of treatments recommended will vary based on your clinical circumstances, but an initial plan will be outlined for you by your doctor.
Most cycles range from 2 to 6 weeks. The number of treatment doses scheduled within each cycle also depends on the prescribed chemotherapy. For example, each cycle may contain only 1 dose on the first day. Or, a cycle may contain more than 1 dose given each week or each day.
Abstract. Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). Increasingly, low-dose once-a-week cisplatin is substituted because of perceived lower toxicity and convenience.Dec 8, 2017
Presently, cisplatin is one of the most powerful chemotherapeutic drugs used for the treatment of ovarian cancer; even though resistance is typical [20]. In ovarian germ cell cancer, the use of cisplatin brings about high response rates [21].Apr 8, 2019
Your course of chemotherapy Each cycle of cisplatin usually takes 21 days (3 weeks). You usually have the cisplatin on the first day of each cycle. But this will depend on the type of cancer you have. Your doctor or nurse will discuss your treatment plan with you.
Cisplatin Injection (cisplatin injection (cisplatin (cisplatin injection) injection) ) is a sterile aqueous solution, available in 50, 100 and 200 mL multiple dose vials, each mL containing 1 mg of cisplatin (cisplatin injection) and 9 mg sodium chloride in water for injection.
Cisplatin may cause serious kidney problems. Tell you doctor right away if you have blood in urine, change in frequency of urination or amount of urine, difficulty in breathing, drowsiness, increased thirst, loss of appetite, nausea or vomiting, swelling of the feet or lower legs, or weakness.Feb 1, 2022
How often will I Therapy? Chemotherapy drugs are typically given in cycles. The cycle consists of the day(s) the drug is administered followed by a rest and recovery period. A cycle usually lasts one to four weeks and is then repeated, which means a treatment is administered every one to four weeks.
Average length of chemotherapy One course of chemo treatment may last between 3 to 6 months. Typically, one course consists of several on-and-off cycles. One cycle usually lasts 2 to 6 weeks. Within each cycle, there are multiple treatment sessions.Apr 13, 2021
You can have chemotherapy once a week or for several days, then rest for several days or weeks. The breaks give the drugs time to do their job. Rest also gives your body time to heal so you can handle side effects like nausea, hair loss, or fatigue. Each set of doses is called a cycle.Feb 13, 2022
Testicular cancer that has metastasized. It is used with other drugs in patients who have already had surgery or radiation therapy. Cisplatin is also being studied in the treatment of other types of cancer.
Use in Cancer. Cisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced disease that cannot be treated with other therapies, such as surgery or radiation therapy. Ovarian cancer that has metastasized (spread to other parts of the body).
Cisplatin has a molecular weight of 301.1 gm/mol, a density of 3.74 g/cm3, a melting point of 270° C, a log Kowof -2.19 and a water solubility of 2.53 g/L at 25° C (HSDB 2009). Cisplatin was first synthesized by M. Peyrone in 1844 and its chemical structure was first elucidated by Alfred Werner in 1893.
The diminished reactivity limits protein-carboplatin complexes, which are excreted. The lower excretion rate of carboplatin means that more is retained in the body, and hence its effects are longer lasting (a retention half-life of 30 hours for carboplatin, compared to 1.5-3.6 hours in the case of cisplatin).
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It has been extensively used for the cure of different types of neoplasms including head and neck, lung, ovarian, leukemia, breast, brain, kidney and testicular cancers.
This has led to interest in platinum (II) - and other metal-containing compounds as potential anticancer drugs (Frezza, Hindo et al., 2010). Cisplatin is clinically proven to combat different types of cancers including sarcomas, cancers of soft tissue, bones, muscles, and blood vessels.
At present, to study the thermodynamics and kinetics of not only cisplatin–DNA complexes, but also of other complexes such as Pt(II)-based cisplatin analogs, other transition metal complexes, and DNA binding organic molecules, both quantum mechanical and molecular mechanical methods are being used.
Cisplatin is an important chemotherapeutic agent used widely or the treatment of a variety of malignancies, including breast, testicular, ovarian, cervical, prostate, head and neck, bladder, lung and refractory non-Hodgkin's lymphomas (Tsimberidou, Braiteh et al., 2009;Dhar, Kolishetti et al., 2011).
It is a white or deep yellow to yellow-orange crystalline powder at room temperature. It is slightly soluble in water and soluble in dimethylprimanide and N,N- dimethyl formamide. Cisplatin is stable under normal temperatures and pressures, but may transform slowly over time to the trans-isomer (IARC 1981, Akron 2009).
How Cisplatin Is Given: Cisplatin is administered through a vein (intravenously or IV) as an infusion. There is no pill form of cisplatin. Cisplatin is an irritant. An irritant is a chemical that can cause inflammation of the vein through which it is given. If cisplatin escapes from the vein it can cause tissue damage.
The following side effects are common (occurring in greater than 30%) for patients taking Cisplatin: Nausea and vomiting. Nausea may last up to 1 week after therapy.
Cisplatin. (SIS pla tin) Trade Names: Platinol®, Platinol®-AQ. Other Name: CDDP. Cisplatin is the generic name for the trade name drug Platinol® and Platinol®-AQ. In some cases, health care professionals may use the trade name Platinol® and Platinol®-AQ, or other names such as CDDP, when referring to the generic drug name cisplatin. Drug Type:
If cisplatin escapes from the vein it can cause tissue damage. The nurse or doctor who gives cisplatin must be carefully trained. If you experience pain or notice redness or swelling at the IV site while you are receiving cisplatin, alert your health care professional immediately.
Before and/or after the cisplatin infusion, extra IV fluids are given and care is taken to ensure adequate hydration before both during and after cisplatin, to protect your kidney function. Cisplatin also has been used as an infusion into the abdominal cavity (contains the abdominal organs).
Hair loss may cause hair loss; however, this side effect is uncommon. Not all cisplatin side effects are listed above, some that are rare (occurring in less than 10% of patients) are not listed here. However, you should always inform your health care provider if you experience any unusual symptoms.
Cisplatin side effects are often predictable in terms of their onset, duration, and severity. Cisplatin side effects will improve after therapy is complete. Cisplatin side effects may be quite manageable. There are many options to help minimize or prevent the side effects of cisplatin.
Cisplatin is usually used in combination with other medicines. Patients will have regular blood tests to check blood counts and monitor kidney and liver function. Doctors will also monitor how much the patient is drinking and urinating as well as blood levels of magnesium, potassium, calcium, sodium, and phosphorus.
Possible late effects due to cisplatin include: Fertility problems. Delayed puberty. Secondary cancers.
Numbness or tingling of the hands or feet. Low levels of magnesium, potassium, calcium, sodium, or phosphorus in the blood. Change in the normal menstrual cycle. Infertility. Not all patients who take cisplatin will experience these side effects. Common side effects are in bold, but there may be others.
Cisplatin can cause tissue damage if it leaks from the vein. Patients may have irritation and skin damage at the IV site. Let a caregiver know if there is burning during administration. Given as a liquid into a vein by IV.
Patients may receive IV fluids before and after receiving cisplatin. Let a doctor know if the patient urinates less often than normal after receiving cisplatin.
The side effects can be serious – they vary from patient to patient of course – but hundreds of thousands of people have been given cisplatin and the medical establishment has learned how to deal with it.
The chemical formula is Pt (NH3)2Cl2. Molecular weight is 300.045. Cisplatin is soluble in water and delivered to the body in aqueous form. Public Domain image from National Cancer Institute.
Cisplatin is called the “penicillin of cancer” because it is used so widely and it was the first big chemotherapy drug. Cisplatin also plays an interesting role in the history of chemistry. First synthesized in the 1800s, long before anyone thought of using it against cancer, cisplatin was a target compound chemists used to prove their moxie in inorganic synthesis. The shape and symbols of the molecule as represented in that discipline's iconography is aesthetically pleasing which is another reason people like to talk about cisplatin.
By the late 1970s it was widely used and is still used today despite the many newer chemotherapy drugs developed over the past decades. Cancer Research UK has a great article about how cisplatin came to be recognized as a cancer drug. Cisplatin is off-patent.
New chemotherapy drugs have arrived on the scene over the past few decades, but cisplatin still finds wide use. Even when it is not the only or main drug given the the cancer patient, it can be a valuable part of a combination chemotherapy regimen. Look at the regimens given to patients and you will often see cisplatin as one of the drugs.
Implications for Practice. Deliver hydration to patients receiving cisplatin therapy to maintain renal function. Include magnesium supplementation, which has nephroprotective effects in adults, in hydration regimens before, during, and after cisplatin. Add mannitol to hydration to prevent nephrotoxicity in adults.
Patients may accumulate metabolites in the renal proximal tubule cells of the kidneys, where 90% of cisplatin undergoes urinary excretion, Duffy et al. explained. This causes a trifecta of factors: direct inflammation, production of reactive oxygen species leading to oxidative cell damage, and cell death.
Evidence for Nephrotoxicity Prevention With Cisplatin Therapy Is Still Limited. Cisplatin chemotherapy is used alone or in combination to treat a variety of cancers, including ovarian, testicular, lung, cervical, bladder, head and neck, and gastric cancers as well as lymphoma, melanoma, and more. Although it offers options for many cancer types, ...
Some references recommend that cisplatin be infused over several hours in solution with mannitol, 2 however this duration of cisplatin infusion is not appropriate for many chemotherapy regimens. Pages: 1 2.
Cisplatin is used for the treatment of many cancers. One dose-limiting adverse effect of cisplatin is nephrotoxicity. Cisplatin is predominantly excreted by the kidneys, and concentrations in the kidneys are higher than in the blood or other tissues.
Cisplatin also causes nephrotoxicity by causing vasoconstriction in the renal microvasculature, reduced renal blood flow, and expression of pro-inflammatory cytokines. Nephrotoxicity due to cisplatin is cumulative and associated with higher doses and duration of therapy.
Mechanism of Action. The main mechanism of the cytotoxic action involves the binding of Cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.
Neurologic symptoms have been reported to occur after a single dose. Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of Cisplatin for injection.
Plasmapheresis has been used to treat cases of Cisplatin for injection overdosage , but the optimal treatment regimen has not been established. For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.
Cisplatin for injection, USP, a platinum-based drug for intravenous use, is a white to light yellow lyophilized powder. Each vial of Cisplatin for injection, USP contains 50 mg Cisplatin, 450 mg Sodium Chloride, USP, and 500 mg Mannitol, USP.
Over a dose range of 40 mg to 140 mg Cisplatin per m 2 given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours. Over 5 days following administration of 40 mg/m 2 to 100 mg/m 2 doses given as rapid, 2‑ to 3‑hour or 6‑ to 8‑hour infusions, a mean of 35% to 51% of the dosed platinum is excreted in the urine. Similar mean urinary recoveries of platinum of about 14% to 30% of the dose are found following 5 daily administrations of 20 mg/m 2 per day, 30 mg/m 2 per day, or 40 mg/m 2 per day. Only a small percentage of the administered platinum is excreted beyond 24 hours post-infusion and most of the platinum excreted in the urine in 24 hours is excreted within the first few hours.
Following Cisplatin doses of 20 mg/m 2 to 120 mg/m 2, platinum is present in tissues for as long as 180 days after the last administration.
Cisplatin for injectioncan cause dose-related nephrotoxicity, including acute renal failure that becomes more prolonged and severe with repeated courses of the drug. Renal toxicity typically begins during the second week after a dose ofCisplatin for injection.